Telix ADSs Commence Trading on Nasdaq

In This Article:

Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited

MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol ‘TLX’.

The Company continues to have its primary listing on ASX, with the Nasdaq listing of ADSs expected to complement the Company’s ASX listing.

Each ADS represents one fully paid ordinary share of the Company. Telix has not issued any new shares as part of the Nasdaq listing. Initial trading of ADSs may be limited as existing shareholders take time to transition their TLX shares to ADSs.

JPMorgan Chase Bank. N.A. has been appointed as the depositary, custodian and registrar for the ADS program.

Dr. Christian Behrenbruch, Managing Director and Group Chief Executive Officer, Telix, said, “Listing on Nasdaq is an important milestone and one that will facilitate streamlined access to Telix shares for a significant portion of our workforce, and U.S. and global investors. It is an appropriate step given the growth trajectory of company, leadership position in radiopharmaceuticals and expanding footprint in North America.”

This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

Telix Investor Relations 

Australia 

Ms. Kyahn Williamson 
Telix Pharmaceuticals Limited 
SVP Investor Relations and Corporate Communications 
Email: kyahn.williamson@telixpharma.com

United States  

Lisa Wilson  
In-Site Communications  
Email: lwilson@insitecony.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Board of Directors.